Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes.
| Title: | Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes. |
|---|---|
| Authors: | Pyun JM; Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, 59, Daesagwan-ro, Yongsan-gu, Seoul, 04401, Republic of Korea.; Park YH; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, 13620, Gyeonggi-do, Republic of Korea.; Kang MJ; Department of Neurology, Veterans Health Service Medical Center, 53, Jinhwangdo-ro 61-gil, Gangdong-gu, Seoul, 05368, Republic of Korea.; Kim S; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, 13620, Gyeonggi-do, Republic of Korea. neuroksy@snu.ac.kr. |
| Source: | Alzheimer's research & therapy [Alzheimers Res Ther] 2024 Oct 02; Vol. 16 (1), pp. 210. Date of Electronic Publication: 2024 Oct 02. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BioMed Central Ltd. |
| MeSH Terms: | Cognitive Dysfunction*/diagnostic imaging ; Positron-Emission Tomography*/methods ; Cholinesterase Inhibitors*/therapeutic use; tau Proteins/cerebrospinal fluid ; tau Proteins/metabolism ; Brain/diagnostic imaging ; Brain/pathology ; Amyloid/metabolism ; Humans ; Male ; Female ; Aged ; Aged, 80 and over ; Magnetic Resonance Imaging ; Middle Aged |
| Abstract: | Background: Cholinesterase inhibitors (ChEIs) are prescribed for Alzheimer's disease (AD) and sometimes for mild cognitive impairment (MCI) without knowing underlying pathologies and its effect on cognition. We investigated the frequency of ChEI prescriptions in amyloid-negative MCI and their association with cognitive changes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.; Methods: We included participants with amyloid positron emission tomography (PET)-negative MCI from the ADNI. We analyzed the associations of ChEI use with cognitive changes, brain volume, and cerebrospinal fluid (CSF) total tau (t-tau), hyperphosphorylated tau181 (p-tau181), and p-tau181/t-tau ratio.; Results: ChEIs were prescribed in 27.4% of amyloid PET-negative MCI and were associated with faster cognitive decline, reduced baseline hippocampal volume and entorhinal cortical thickness, and a longitudinal decrease in the frontal lobe cortical thickness.; Conclusions: The association between ChEI use and accelerated cognitive decline may stem from underlying pathologies involving reduced hippocampal volume, entorhinal cortical thickness and faster frontal lobe atrophy. We suggest that ChEI use in amyloid PET-negative MCI patients might need further consideration, and studies investigating the causality between ChEI use and cognitive decline are warranted in the future.; (© 2024. The Author(s).) |
| References: | Arch Neurol. 2006 May;63(5):693-9. (PMID: 16682538); Expert Opin Ther Targets. 2007 Feb;11(2):161-79. (PMID: 17227232); Brain Imaging Behav. 2012 Dec;6(4):502-16. (PMID: 22782295); Ann Neurol. 2009 Apr;65(4):403-13. (PMID: 19296504); Brain. 2018 Jul 1;141(7):1917-1933. (PMID: 29850777); Alzheimers Dement. 2010 May;6(3):212-20. (PMID: 20451869); Brain Imaging Behav. 2012 Dec;6(4):517-27. (PMID: 22644789); Neuropharmacology. 2021 Jun 1;190:108352. (PMID: 33035532); CNS Neurosci Ther. 2011 Oct;17(5):428-41. (PMID: 21951368); Biol Psychiatry. 2000 Jun 15;47(12):1056-63. (PMID: 10862805); Alzheimers Res Ther. 2017 Dec 16;9(1):99. (PMID: 29246250); JAMA Neurol. 2017 Dec 1;74(12):1492-1501. (PMID: 29114726); J Psychiatr Res. 1975 Nov;12(3):189-98. (PMID: 1202204); Neurology. 2018 Jan 16;90(3):126-135. (PMID: 29282327); JAMA Neurol. 2023 Oct 1;80(10):1051-1061. (PMID: 37578787); Neurology. 2013 Nov 26;81(22):1945-52. (PMID: 24174584); Alzheimers Res Ther. 2021 May 10;13(1):99. (PMID: 33971965); Brain. 2019 Jun 1;142(6):1503-1527. (PMID: 31039256); Brain Sci. 2023 Dec 31;14(1):. (PMID: 38248256); Alzheimers Dement. 2019 Feb;15(2):205-216. (PMID: 30347188); Acta Neuropathol. 2011 May;121(5):597-609. (PMID: 21311900); Int J Mol Sci. 2021 Aug 27;22(17):. (PMID: 34502198); Arch Neurol. 2011 Jan;68(1):58-66. (PMID: 21220675); Brain. 2015 Mar;138(Pt 3):772-83. (PMID: 25541191); Molecules. 2022 Mar 10;27(6):. (PMID: 35335180); Alzheimers Dement. 2017 Mar;13(3):205-216. (PMID: 27697430); Brain. 2011 Feb;134(Pt 2):432-48. (PMID: 21252111); J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. (PMID: 12805474); Neurology. 1993 Nov;43(11):2412-4. (PMID: 8232972); J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):767-73. (PMID: 25224676); Neuroimage Clin. 2016 Dec 07;13:470-482. (PMID: 28119818); JAMA Neurol. 2015 Dec;72(12):1501-9. (PMID: 26501846) |
| Grant Information: | U01 AG024904 United States AG NIA NIH HHS |
| Contributed Indexing: | Keywords: Alzheimer’s disease; Cholinesterase inhibitors; Cognitive decline; Mild cognitive impairment |
| Substance Nomenclature: | 0 (Cholinesterase Inhibitors); 0 (tau Proteins); 0 (Amyloid) |
| Entry Date(s): | Date Created: 20241002 Date Completed: 20241003 Latest Revision: 20260416 |
| Update Code: | 20260417 |
| PubMed Central ID: | PMC11448210 |
| DOI: | 10.1186/s13195-024-01580-y |
| PMID: | 39358798 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.